FDA Alerts

FDA ALERT
FDA ALERT
11/30/2023

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/30/2023
FDA
FDA
05/23/2019
The US Food and Drug Administration has granted approval to a foam treatment for plaque psoriasis in adolescents.
05/23/2019
FDA
FDA
05/29/2018
The US Food and Drug Administration has approved expanding the label of a psoriasis drug to include adults with moderate-to-severe plaque psoriasis.
05/29/2018
Psoriasis
Psoriasis
05/22/2018
The FDA has approved a label update for a biologic used for the treatment of adult patients with moderate-to-severe plaque psoriasis
05/22/2018
Psoriasis
Psoriasis
03/21/2018
Following the success of the reSURFACE clinical program, the US Food and Drug Administration has approved a new treatment option for adults with moderate to severe plaque psoriasis.
03/21/2018
Psoriasis
Psoriasis
12/04/2017
The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.
12/04/2017
Psoriasis
Psoriasis
07/14/2017
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.
07/14/2017
Psoriasis
Psoriasis
02/16/2017
The FDA approved the injection Siliq (brodalumab) to treat adults with moderate to severe plaque psoriasis.
02/16/2017
FDA ALERT
FDA ALERT
11/08/2015

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
FDA ALERT
FDA ALERT
11/08/2015

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015